This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eckfeld, K. Articles by Clark, G. J. Search for Related Content PubMed PubMed Citation Articles by Eckfeld, K. Articles by Clark, G. J.

RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family

¹ Department of Cell and Cancer Biology, National Cancer Institute, Rockville, Maryland; ² Section of Medical and Molecular Genetics, Division of Reproductive and Child Health, University of Birmingham, Birmingham, United Kingdom; and ³ Laboratoire d’Oncogenetique-INSERM E0017, Centre Rene Huguenin, St-Cloud, France

Activated Ras proteins interact with a broad range of effector proteins to induce a diverse series of biological consequences. Although typically associated with enhanced growth and transformation, activated Ras may also induce growth antagonistic effects such as senescence or apoptosis. It is now apparent that some of the growth-inhibitory properties of Ras are mediated via the RASSF family of Ras effector/tumor suppressors. To date, four members of this family have been identified (Nore1, RASSF1, RASSF2, and RASSF3). We now identify a fifth member of this group, RASSF4 (AD037). RASSF4 shows approximately 25% identity with RASSF1A and 60% identity with RASSF2. RASSF4 binds directly to activated K-Ras in a GTP-dependent manner via the effector domain, thus exhibiting the basic properties of a Ras effector. Overexpression of RASSF4 induces Ras-dependent apoptosis in 293-T cells and inhibits the growth of human tumor cell lines. Although broadly expressed in normal tissue, RASSF4 is frequently down-regulated by promoter methylation in human tumor cells. Thus, RASSF4 appears to be a new member of the RASSF family of potential Ras effector/tumor suppressors.

This article has been cited by other articles:

				M. Ikeda, A. Kawata, M. Nishikawa, Y. Tateishi, M. Yamaguchi, K. Nakagawa, S. Hirabayashi, Y. Bao, S. Hidaka, Y. Hirata, et al. Hippo Pathway-Dependent and -Independent Roles of RASSF6 Sci. Signal., September 29, 2009; 2(90): ra59 - ra59. [Abstract] [Full Text] [PDF]

				K. Klapproth, S. Sander, D. Marinkovic, B. Baumann, and T. Wirth The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis Blood, September 17, 2009; 114(12): 2448 - 2458. [Abstract] [Full Text] [PDF]

				R. Maruyama, K. Akino, M. Toyota, H. Suzuki, T. Imai, M. Ohe-Toyota, E. Yamamoto, M. Nojima, T. Fujikane, Y. Sasaki, et al. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer Carcinogenesis, July 1, 2008; 29(7): 1312 - 1318. [Abstract] [Full Text] [PDF]

				V. Sherwood, R. Manbodh, C. Sheppard, and A. D. Chalmers RASSF7 Is a Member of a New Family of RAS Association Domain-containing Proteins and Is Required for Completing Mitosis Mol. Biol. Cell, April 1, 2008; 19(4): 1772 - 1782. [Abstract] [Full Text] [PDF]

				Y. Hao, A. Chun, K. Cheung, B. Rashidi, and X. Yang Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP J. Biol. Chem., February 29, 2008; 283(9): 5496 - 5509. [Abstract] [Full Text] [PDF]

				M. Milstein, C. K. Mooser, H. Hu, M. Fejzo, D. Slamon, L. Goodglick, S. Dry, and J. Colicelli RIN1 Is a Breast Tumor Suppressor Gene Cancer Res., December 15, 2007; 67(24): 11510 - 11516. [Abstract] [Full Text] [PDF]

				H. Donninger, M. D. Vos, and G. J. Clark The RASSF1A tumor suppressor J. Cell Sci., September 15, 2007; 120(18): 3163 - 3172. [Abstract] [Full Text] [PDF]

				S. Xia, L. W. Forman, and D. V. Faller Protein Kinase C{delta} Is Required for Survival of Cells Expressing Activated p21RAS J. Biol. Chem., May 4, 2007; 282(18): 13199 - 13210. [Abstract] [Full Text] [PDF]

				A. Moshnikova, J. Frye, J. W. Shay, J. D. Minna, and A. V. Khokhlatchev The Growth and Tumor Suppressor NORE1A Is a Cytoskeletal Protein That Suppresses Growth by Inhibition of the ERK Pathway J. Biol. Chem., March 24, 2006; 281(12): 8143 - 8152. [Abstract] [Full Text] [PDF]

				M. D. Vos, A. Dallol, K. Eckfeld, N. P. C. Allen, H. Donninger, L. B. Hesson, D. Calvisi, F. Latif, and G. J. Clark The RASSF1A Tumor Suppressor Activates Bax via MOAP-1 J. Biol. Chem., February 24, 2006; 281(8): 4557 - 4563. [Abstract] [Full Text] [PDF]

				E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT Blood, December 15, 2005; 106(13): 4322 - 4329. [Abstract] [Full Text] [PDF]

				A. Agathanggelou, W. N. Cooper, and F. Latif Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers Cancer Res., May 1, 2005; 65(9): 3497 - 3508. [Abstract] [Full Text] [PDF]